Unique 3D Tissue Regeneration Technology Platofrm
Location: Belgium, Walloon Brabant, Mont-Saint-Guibert
Employees: 11-50
Total raised: $92.85M
Founded date: 2013
Investors 4
| Date | Name | Website |
| - | Invest.BW | investbw.b... |
| - | Fund+ | fundplus.b... |
| - | Le Groupe ... | sriw.be |
| - | New Scienc... | newscience... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.11.2022 | Series B | $39.19M | - |
| 28.10.2021 | Series B | $22.05M | - |
| 10.09.2015 | Series A | $31.6M | - |
Mentions in press and media 14
| Date | Title | Description |
| 29.04.2025 | Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb | No refractures were reported during long-term follow-up at five years At 24-months post-implantation, 89% of patients achieved bone union Novadip plans market launch of NVD003 in 2027 Mont Saint-Guibert, Belgium, April 29, 2025 – Novadip Bi... |
| 24.04.2025 | Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion | Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (... |
| 17.10.2024 | Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field | At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached or are steadily progressing towards complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique “Off the Shelf” al... |
| 27.12.2022 | Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer | Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today anno... |
| 09.12.2022 | Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma | Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment |
| 04.11.2022 | Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million | Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures |
| 03.11.2022 | Novadip Biosciences Raises Additional EUR 40M in Series B Funding | Novadip Biosciences, a Mont Saint-Guibert, Belgium-based clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, raised ... |
| 20.12.2021 | Intertrust N : Why investors should check out Belgium's world-leading biotech industry | Make an enquiry The country's industrial heritage allied with strong government incentives to help it play a leading role in the race to develop Covid vaccines, say Business Development Manager Brecht Guldemont and Managing Director Christo... |
| 28.10.2021 | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors New investment to fuel continued growth of 3M³ platform for the development of products in tissue reconstruction and oncology Mont Saint-Guibe... |
| 28.10.2021 | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors |
Show more